We are analyzing https://link.springer.com/article/10.1007/s00262-008-0568-4.

Title:
Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters | Cancer Immunology, Immunotherapy
Description:
During the past years numerous clinical trials have been carried out to assess the ability of dendritic cell (DC) based immunotherapy to induce clinically relevant immune responses in patients with malignant diseases. A broad range of cancer types have been targeted including malignant melanoma which in the disseminated stage have a very poor prognosis and only limited treatment options with moderate effectiveness. Herein we describe the results of a focused search of recently published clinical studies on dendritic cell vaccination in melanoma and review different vaccine parameters which are frequently claimed to have a possible influence on clinical response. These parameters include performance status, type of antigen, DC maturation status, route of vaccine administration, use of adjuvant, and vaccine induced immune response. In total, 38 articles found through Medline search, have been included for analysis covering a total of 626 patients with malignant melanoma treated with DC based therapy. Clinical response (CR, PR and SD) were found to be significantly correlated with the use of peptide antigens (p = 0.03), the use of any helper antigen/adjuvant (p = 0.002), and induction of antigen specific T cells (p = 0.0004). No significant correlations between objective response (CR and PR) and the tested parameters were found. However, a few non-significant trends were demonstrated; these included an association between objective response and use of immature DCs (p = 0.08), use of adjuvant (p = 0.09), and use of autologous antigen preparation (p = 0.12). The categorisation of SD in the response group is debatable. Nevertheless, when the SD group were analysed separately we found that SD was significantly associated with use of peptide antigens (p = 0.0004), use of adjuvant (p = 0.01), and induction of antigen specific T cells (p = 0.0003). No specific route of vaccine administration showed superiority. Important lessons can be learned from previous studies, interpretation of these findings should, however, be done with reservation for the many minor deviations in the different treatment schedules among the published studies, which were not considered in order to be able to process and group the data.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Education
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don't see any clear sign of profit-making.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Link.springer.com has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

google, scholar, dendritic, pubmed, article, cas, cells, melanoma, cancer, patients, cell, immunol, clinical, immunother, response, vaccination, vaccine, phase, autologous, metastatic, immunotherapy, res, tumor, immune, responses, blood, treatment, antigen, peptide, tumour, human, clin, stage, immunity, trial, monocytederived, interleukin, mature, study, malignant, specific, vaccines, med, iii, svane, results, gmcsf, tcell, oncol, search,

Topics {✒️}

granulocyte/macrophage colony-stimulating factor granulocyte-macrophage colony-stimulating factor mage-3a1 peptide-pulsed mature monocyte-derived dendritic cells melanoma-specific t-cell responses tumor lysate-pulsed mature month download article/chapter monocyte/dendritic cell precursors inge marie svane high-level il-12 production interferon-beta induces cd8+ dendritic cell-based vaccination p53 specific t-cells adoptive t-cell transfer dc-based cancer vaccines article engell-noerregaard article cancer immunology autologous tumour cells na17-a2 tumor peptide melanoma patient-specific vaccine autologous tumor-mrna dendritic cell vaccines antitumor t-cell response dendritic cell immunotherapy optimized ctl-inducing activity dendritic cells transfected autologous dendritic cell antigen-specific cd8 mature dendritic cells allogeneic tumor lysate autologous antigen preparation human dendritic cells dendritic cells loaded full article pdf dendritic cell vaccination dendritic cell differentiation dendritic cell immunizations dendritic cell phenotype t-cell immunity hematopoietic progenitor cells tumor-specific type 1 dendritic cells injected matured dendritic cells related subjects privacy choices/manage cookies malignant melanoma treated t-cell response stage iv melanoma gm-csf + il-4 thor straten

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters
         description:During the past years numerous clinical trials have been carried out to assess the ability of dendritic cell (DC) based immunotherapy to induce clinically relevant immune responses in patients with malignant diseases. A broad range of cancer types have been targeted including malignant melanoma which in the disseminated stage have a very poor prognosis and only limited treatment options with moderate effectiveness. Herein we describe the results of a focused search of recently published clinical studies on dendritic cell vaccination in melanoma and review different vaccine parameters which are frequently claimed to have a possible influence on clinical response. These parameters include performance status, type of antigen, DC maturation status, route of vaccine administration, use of adjuvant, and vaccine induced immune response. In total, 38 articles found through Medline search, have been included for analysis covering a total of 626 patients with malignant melanoma treated with DC based therapy. Clinical response (CR, PR and SD) were found to be significantly correlated with the use of peptide antigens (p = 0.03), the use of any helper antigen/adjuvant (p = 0.002), and induction of antigen specific T cells (p = 0.0004). No significant correlations between objective response (CR and PR) and the tested parameters were found. However, a few non-significant trends were demonstrated; these included an association between objective response and use of immature DCs (p = 0.08), use of adjuvant (p = 0.09), and use of autologous antigen preparation (p = 0.12). The categorisation of SD in the response group is debatable. Nevertheless, when the SD group were analysed separately we found that SD was significantly associated with use of peptide antigens (p = 0.0004), use of adjuvant (p = 0.01), and induction of antigen specific T cells (p = 0.0003). No specific route of vaccine administration showed superiority. Important lessons can be learned from previous studies, interpretation of these findings should, however, be done with reservation for the many minor deviations in the different treatment schedules among the published studies, which were not considered in order to be able to process and group the data.
         datePublished:2008-08-22T00:00:00Z
         dateModified:2008-08-22T00:00:00Z
         pageStart:1
         pageEnd:14
         sameAs:https://doi.org/10.1007/s00262-008-0568-4
         keywords:
            Cancer
            Dendritic cells
            Malignant melanoma
            Immunotherapy
            Tumour vaccines
            Oncology
            Immunology
            Cancer Research
         image:
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:58
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Lotte Engell-Noerregaard
               affiliation:
                     name:Herlev Hospital
                     address:
                        name:Department of Oncology, Herlev Hospital, Herlev, Denmark
                        type:PostalAddress
                     type:Organization
                     name:Herlev Hospital
                     address:
                        name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev Hospital, Herlev, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Troels Holz Hansen
               affiliation:
                     name:Herlev Hospital
                     address:
                        name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev Hospital, Herlev, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Mads Hald Andersen
               affiliation:
                     name:Herlev Hospital
                     address:
                        name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev Hospital, Herlev, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Per thor Straten
               affiliation:
                     name:Herlev Hospital
                     address:
                        name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev Hospital, Herlev, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Inge Marie Svane
               affiliation:
                     name:Herlev Hospital
                     address:
                        name:Department of Oncology, Herlev Hospital, Herlev, Denmark
                        type:PostalAddress
                     type:Organization
                     name:Herlev Hospital
                     address:
                        name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev Hospital, Herlev, Denmark
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters
      description:During the past years numerous clinical trials have been carried out to assess the ability of dendritic cell (DC) based immunotherapy to induce clinically relevant immune responses in patients with malignant diseases. A broad range of cancer types have been targeted including malignant melanoma which in the disseminated stage have a very poor prognosis and only limited treatment options with moderate effectiveness. Herein we describe the results of a focused search of recently published clinical studies on dendritic cell vaccination in melanoma and review different vaccine parameters which are frequently claimed to have a possible influence on clinical response. These parameters include performance status, type of antigen, DC maturation status, route of vaccine administration, use of adjuvant, and vaccine induced immune response. In total, 38 articles found through Medline search, have been included for analysis covering a total of 626 patients with malignant melanoma treated with DC based therapy. Clinical response (CR, PR and SD) were found to be significantly correlated with the use of peptide antigens (p = 0.03), the use of any helper antigen/adjuvant (p = 0.002), and induction of antigen specific T cells (p = 0.0004). No significant correlations between objective response (CR and PR) and the tested parameters were found. However, a few non-significant trends were demonstrated; these included an association between objective response and use of immature DCs (p = 0.08), use of adjuvant (p = 0.09), and use of autologous antigen preparation (p = 0.12). The categorisation of SD in the response group is debatable. Nevertheless, when the SD group were analysed separately we found that SD was significantly associated with use of peptide antigens (p = 0.0004), use of adjuvant (p = 0.01), and induction of antigen specific T cells (p = 0.0003). No specific route of vaccine administration showed superiority. Important lessons can be learned from previous studies, interpretation of these findings should, however, be done with reservation for the many minor deviations in the different treatment schedules among the published studies, which were not considered in order to be able to process and group the data.
      datePublished:2008-08-22T00:00:00Z
      dateModified:2008-08-22T00:00:00Z
      pageStart:1
      pageEnd:14
      sameAs:https://doi.org/10.1007/s00262-008-0568-4
      keywords:
         Cancer
         Dendritic cells
         Malignant melanoma
         Immunotherapy
         Tumour vaccines
         Oncology
         Immunology
         Cancer Research
      image:
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:58
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Lotte Engell-Noerregaard
            affiliation:
                  name:Herlev Hospital
                  address:
                     name:Department of Oncology, Herlev Hospital, Herlev, Denmark
                     type:PostalAddress
                  type:Organization
                  name:Herlev Hospital
                  address:
                     name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev Hospital, Herlev, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Troels Holz Hansen
            affiliation:
                  name:Herlev Hospital
                  address:
                     name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev Hospital, Herlev, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Mads Hald Andersen
            affiliation:
                  name:Herlev Hospital
                  address:
                     name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev Hospital, Herlev, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Per thor Straten
            affiliation:
                  name:Herlev Hospital
                  address:
                     name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev Hospital, Herlev, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Inge Marie Svane
            affiliation:
                  name:Herlev Hospital
                  address:
                     name:Department of Oncology, Herlev Hospital, Herlev, Denmark
                     type:PostalAddress
                  type:Organization
                  name:Herlev Hospital
                  address:
                     name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev Hospital, Herlev, Denmark
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:58
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Herlev Hospital
      address:
         name:Department of Oncology, Herlev Hospital, Herlev, Denmark
         type:PostalAddress
      name:Herlev Hospital
      address:
         name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev Hospital, Herlev, Denmark
         type:PostalAddress
      name:Herlev Hospital
      address:
         name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev Hospital, Herlev, Denmark
         type:PostalAddress
      name:Herlev Hospital
      address:
         name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev Hospital, Herlev, Denmark
         type:PostalAddress
      name:Herlev Hospital
      address:
         name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev Hospital, Herlev, Denmark
         type:PostalAddress
      name:Herlev Hospital
      address:
         name:Department of Oncology, Herlev Hospital, Herlev, Denmark
         type:PostalAddress
      name:Herlev Hospital
      address:
         name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev Hospital, Herlev, Denmark
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Lotte Engell-Noerregaard
      affiliation:
            name:Herlev Hospital
            address:
               name:Department of Oncology, Herlev Hospital, Herlev, Denmark
               type:PostalAddress
            type:Organization
            name:Herlev Hospital
            address:
               name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev Hospital, Herlev, Denmark
               type:PostalAddress
            type:Organization
      name:Troels Holz Hansen
      affiliation:
            name:Herlev Hospital
            address:
               name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev Hospital, Herlev, Denmark
               type:PostalAddress
            type:Organization
      name:Mads Hald Andersen
      affiliation:
            name:Herlev Hospital
            address:
               name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev Hospital, Herlev, Denmark
               type:PostalAddress
            type:Organization
      name:Per thor Straten
      affiliation:
            name:Herlev Hospital
            address:
               name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev Hospital, Herlev, Denmark
               type:PostalAddress
            type:Organization
      name:Inge Marie Svane
      affiliation:
            name:Herlev Hospital
            address:
               name:Department of Oncology, Herlev Hospital, Herlev, Denmark
               type:PostalAddress
            type:Organization
            name:Herlev Hospital
            address:
               name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev Hospital, Herlev, Denmark
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Oncology, Herlev Hospital, Herlev, Denmark
      name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev Hospital, Herlev, Denmark
      name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev Hospital, Herlev, Denmark
      name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev Hospital, Herlev, Denmark
      name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev Hospital, Herlev, Denmark
      name:Department of Oncology, Herlev Hospital, Herlev, Denmark
      name:Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev Hospital, Herlev, Denmark
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(231)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

4.54s.

LINK . SPRINGER . COM {}